Get the Stockscreener App
10.65
3.45%
-0.38
Tyra Biosciences Inc stock is traded at $10.65, with a volume of 21,456.
It is down -3.45% in the last 24 hours and up +10.82% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$11.03
Open:
$11
24h Volume:
21,456
Relative Volume:
0.07
Market Cap:
$565.14M
Revenue:
-
Net Income/Loss:
$-83.74M
P/E Ratio:
-6.6149
EPS:
-1.61
Net Cash Flow:
$-64.98M
1W Performance:
-2.56%
1M Performance:
+10.82%
6M Performance:
-15.94%
1Y Performance:
-45.38%
1-Day Range:
$10.57
$11.00
1-Week Range:
$10.00
$11.72
52-Week Range:
$6.42
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
10.64 | 608.89M | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.43 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.06 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.09 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Will Tyra Biosciences Inc. see short term momentumPattern Breakout Prediction for Short Term - Newser
How institutional ownership impacts Tyra Biosciences Inc. stockEarly Entry Planner for Swing Candidates - Newser
How to integrate Tyra Biosciences Inc. into portfolio analysis toolsShort-Term Support and Resistance Forecast - Newser
Full technical analysis of Tyra Biosciences Inc. stockFree Weekly Stock Opportunity Radar Scanner - Newser
Visual trend scoring systems applied to Tyra Biosciences Inc.Buy and Hold Strategy for Capital Safety - Newser
Technical analysis overview for Tyra Biosciences Inc. stockChart Based Entry Tool for ROI Traders - Newser
Why Tyra Biosciences Inc. stock attracts strong analyst attentionEarly Entry Planner for Swing Candidates - Newser
What machine learning models say about Tyra Biosciences Inc.Price Action Trading with Volume Confirmation - Newser
Combining price and volume data for Tyra Biosciences Inc.Daily Technical Chart Pattern Analysis Report - Newser
News impact scoring models applied to Tyra Biosciences Inc.Tactical Trade Setup With Entry Optimizer - Newser
Bank of New York Mellon Corp Sells 3,924 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
What makes Tyra Biosciences Inc. stock attractive to long term investorsInvestment Roadmap for High Potential Stocks - Newser
Can Tyra Biosciences Inc. recover in the next quarterShort-Term Swing Opportunity Summary Sheet - Newser
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
How Tyra Biosciences Inc. stock performs during market volatilityMachine Learning Stock Movement Detector - Newser
Relative strength of Tyra Biosciences Inc. in sector analysisFree Swing Trading Entry Point Signals - Newser
What are Tyra Biosciences Inc. company’s key revenue driversDiscover undervalued opportunities early - Jammu Links News
When is Tyra Biosciences Inc. stock expected to show significant growthDiscover undervalued stocks before they soar - Jammu Links News
Why is Tyra Biosciences Inc. stock attracting strong analyst attentionAchieve fast wealth growth with smart picks - Jammu Links News
What drives Tyra Biosciences Inc. stock priceRobust financial gains - Jammu Links News
What are the latest earnings results for Tyra Biosciences Inc.Overwhelming profit margins - Jammu Links News
How strong is Tyra Biosciences Inc. company’s balance sheetGet exclusive market analysis for investors - Jammu Links News
Should I hold or sell Tyra Biosciences Inc. stock in 2025Uncover the best stocks for explosive growth - Jammu Links News
Is Tyra Biosciences Inc. a growth stock or a value stockFree Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Tyra Biosciences Inc. stockExtraordinary performance - Jammu Links News
How does Tyra Biosciences Inc. generate profit in a changing economyGet real-time alerts on top stocks - Jammu Links News
Is it the right time to buy Tyra Biosciences Inc. stockFree Advanced Stock Screener Access - Jammu Links News
Published on: 2025-08-03 14:27:08 - Jammu Links News
Tyra Biosciences Inc. Stock Analysis and ForecastSkyrocketing investment returns - Jammu Links News
What is the risk reward ratio of investing in Tyra Biosciences Inc. stockDiscover market opportunities with expert help - Jammu Links News
What are analysts’ price targets for Tyra Biosciences Inc. in the next 12 monthsInvest confidently with market-leading analysis - Jammu Links News
Does Tyra Biosciences Inc. stock perform well during market downturnsDiscover top stock picks for aggressive growth - Jammu Links News
What moving averages say about Tyra Biosciences Inc.Reversal Pattern Insights with Entry Tips - Newser
What institutional flow reveals about Tyra Biosciences Inc.Free Access to Real-Time Trade Insights - Newser
How to recover losses in Tyra Biosciences Inc. stockDownside Risk Evaluation and Stock Analysis - Newser
Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ - openPR.com
Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ Emerging Therapies Target FGFR2, IDH1/2, and Beyond | DelveInsight - The Globe and Mail
What risks could impact Tyra Biosciences Inc. stock performanceReal Market Tracker with Price Action Tools - Newser
What indicators show strength in Tyra Biosciences Inc.Free Price Action Based Buy Opportunity List - Newser
Will Tyra Biosciences Inc. stock benefit from AI tech trendsExpert-Backed High Yield Stock Watchlist - Newser
Is this a good reentry point in Tyra Biosciences Inc.Real-Time Entry Forecast with Accuracy Metrics - Newser
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tyra Biosciences Inc Stock (TYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KAPLAN GILLA | Director |
Jun 17 '25 |
Sale |
10.35 |
10 |
104 |
37,799 |
0.36%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):